
Alpha Arbutin: Targets melanin production; clinical data mainly involve combination creams. Kojic Acid: May help uneven pigmentation, often as part of a combination treatment.


Consider for uneven tone; do not assume it matches prescription pigment treatments.
Consider for uneven pigment if tolerated; evidence is mainly for combinations.
Can you use both?
Often found together in brightening serums. Kojic acid can irritate some skin.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Acts on pigment pathways: Laboratory models show reduced tyrosinase activity. Less melanin is made: Topical results depend on the finished formula.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Reduces tyrosinase activity: Kojic acid interferes with melanin production. Less new pigment forms: Effects depend on the formula and tolerance.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Alpha-arbutin percentages need a regional and product-type context. EU cosmetic limits are 2% in face creams and 0.5% in body lotions; these are safety limits, not proven optimal treatment doses.
0.5%
2%
EU body-lotion ceiling
A maximum for the specified EU product category, not a minimum effective concentration.
EU face-cream ceiling
A maximum for the specified EU product category. It does not establish that 2% will work better than every lower-strength formula.
Choosing a strength: Check that the ingredient is alpha-arbutin. Beta-arbutin has different specifications and should not share the same strength scale.
Higher strengths: A higher concentration in a clinical combination study does not override current cosmetic restrictions or establish safe home use.
Formula matters: The extract or ingredient identity, purity and the finished formula matter. Hydroquinone impurities must be controlled.
Kojic acid concentrations in older studies differ from current cosmetic limits. In the EU, kojic acid is limited to 1% in face and hand products; that is not a universal treatment target.
1%
2%
EU cosmetic ceiling
The maximum in specified face and hand products. This is a regulatory limit, not proof of the best efficacy.
Older combination-study strength
Studied with hydroquinone and glycolic acid. The combination result does not isolate kojic acid or establish a current home-use recommendation.
Choosing a strength: Check local rules and the full formula. Kojic acid and kojic dipalmitate are different ingredients and cannot be compared by percentage alone.
Higher strengths: Do not use an older trial’s concentration as a reason to exceed current limits. Irritation or allergic contact dermatitis can occur.
Formula matters: Combination products may obtain benefit from several ingredients. A study of a combination cannot tell you what kojic acid alone contributed.
Approximate windows, not promises.
First few weeksAssess tolerance first; pigment change is usually slower.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksSome studied regimens begin showing pigment improvement.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksA useful review point for benefit and irritation.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
May cause irritation or a rash; choose a compliant commercial formula.
Can cause stinging, redness or contact dermatitis.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Because it releases small amounts of hydroquinone, ask rather than assume; pregnancy-specific data are limited. Ask the doctor managing your pregnancy. Azelaic acid and strict sun protection are the usual suggestions meanwhile.
There is not much pregnancy-specific data on kojic acid, and melasma often appears or worsens in pregnancy. Ask the doctor managing your pregnancy first. Azelaic acid and strict sun protection are the usual alternatives.
On the skin. The finished product delivers alpha arbutin in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Laboratory models show reduced tyrosinase activity and melanin production; clinical delivery and formula matter.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers kojic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Inhibits tyrosinase activity involved in melanin production; cosmetic formulas differ from studied combinations.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Consider for uneven tone; do not assume it matches prescription pigment treatments.
A 30-person split-face trial tested alpha-arbutin together with kojic acid. Laboratory results cannot establish clinical efficacy alone, and nonsignificant differences do not prove equivalence.
Consider for uneven pigment if tolerated; evidence is mainly for combinations.
A 40-woman split-face trial added kojic acid to hydroquinone and glycolic acid. It does not show that kojic acid alone performs as well as the combination or that higher strengths are better.
Sources